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ABSTRACT 
The direct local delivery of short interfering RNA (siRNA) to tissues may present solutions to 
several complex medical conditions.  In particular, chronic wound healing is a serious and 
painful complication of diabetes mellitus (DM) affecting as many as one in four patients  with a 
three year recurrence rate of more than 50% and leaving over 70,000 patients in the United 
States alone facing amputation.  Here we describe the use of siRNA delivered locally into the 
diabetic ulcer directly and in a sustained fashion to knockdown a chronically upregulated 
extracellular matrix protease, matrix metalloproteinase-9 (MMP-9), to improve wound healing. 
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A self-assembled polymer thin film coating, when applied conformally to commercially 
available nylon bandages, sustains the delivery of small interfering RNA (siRNA) into the 
wound bed while maintaining activity and facilitating transfection.  This approach reduces 
protein expression and enzyme activity within the wound for over two weeks, leading to a 
significant improvement in chronic wound healing. 
INTRODUCTION  
Impaired wound healing is a critical concern in the care of diabetic patients.  Every year there are 
more than 750,000 new cases of diabetic foot ulcers (DFUs) in the United States, leading to over 
70,000 lower limb amputations[1].  In healthy patients, wound healing is a highly orchestrated 
process of overlapping phases: hemostasis, inflammation, tissue formation, and tissue 
remodeling[2].   In ulcerative wound healing this process is interrupted and the wound persists in 
an inflamed state for weeks to months and in many cases never resolves.  The pathology of the 
diabetic ulcer results from this chronic inflammation, due in part to the overexpression of 
extracellular matrix (ECM) proteases in the wound bed[3-5].  As a result, ECM accumulation 
within the DFU is dramatically reduced, impeding epithelial closure of the wound and 
significantly increasing the risk of infection[6].  Many of the current pharmacologic therapies for 
DFU have tried to address this issue through either the delivery of super-physiological 
concentrations of recombinant growth factors, stem cell therapies[7], or application of lab-grown 
dermal substitutes[8, 9]; however, these have proven to be inconsistent, difficult to maintain, and 
have led in some cases to serious undesired side effects[8].       
Over the past two decades numerous groups have correlated overexpression of matrix 
metalloproteinase-9 (MMP-9) within chronic ulcers to poor wound healing outcomes in diabetic 
patients[10].  MMP-9 acts as the primary gelatinase expressed within the dermis after wounding 
and plays a crucial role in ECM degradation and tissue reorganization during the healing 
process[11, 12].  However, overexpression impairs the formation of granulation tissue, the early 
connective tissue that fills a wound, as well as inactivates important growth factors that are 
critical to the process of wound healing[13].  These and other complications of MMP 
overexpression have spurred substantial research into developing MMP inhibitors; however, 
efforts have been hampered by low specificity, poor bioavailability, and serious musculoskeletal 
side effects[14].  In order to address these issues, we hypothesized that using RNA interference 
(RNAi) locally to reduce MMP-9 expression in the wound would be an effective approach for 
increasing ECM accumulation within the wound bed and improving wound healing. 
RNAi using small interfering RNA (siRNA) technology is a promising approach for the 
sequence-specific targeting of mRNAs for destruction, enabling the knockdown of virtually any 
expressed protein[15].  While the potential applications of RNAi in medicine are numerous, in 
vivo delivery of siRNA remains a major obstacle due to rapid enzymatic degradation of siRNAs 
and clearance via the hepatic and renal systems[16].  Local delivery circumvents many of the 
challenges of delivery, but siRNA must still be protected from enzymatic degradation and 
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effectively enter target cells within the tissues of interest.  Only a few systems have been 
developed for local siRNA delivery; those that have rely on bulky hydrogel formulations that 
must be injected directly into tissues[17] or re-purposed nanoparticle solutions that must be 
applied multiple times to achieve efficacy[18].  Neither of these approaches has been 
demonstrated to treat a known medical condition (i.e., pathologic dysregulation) within tissues.  
Furthermore, there are unique challenges that are still to be met in this new area, including the 
ability to easily combine siRNA delivery and release with existing medical technologies and 
platforms.  Layer-by-Layer (LbL) technology has been demonstrated in a myriad of biomedical 
applications for delivery from a broad range of material surfaces, including stainless steel and 
degradable polymer matrices.[19]  We have previously demonstrated that LbL incorporation and 
delivery of siRNA can achieve significant and sustained knockdown of reporter genes in vitro[20], 
although the ability to translate these results to a more complex environment in vivo remained 
unknown.  Therefore, developing this technology to effectively deliver siRNA to a localized area 
in vivo using a meaningful therapeutic gene target presents a significant advancement for the 
treatment of site-specific disorders, including DFUs as well as cardiovascular diseases, cancers, 
and transplant rejection.   
Here we report the use of LbL to achieve significant knockdown of a target gene within a highly 
proteolytic wound bed, with the effects sustained for at least two weeks.  Using a commercially 
available nylon bandage as a substrate, we show that self-assembled nanometer-scale coatings 
can incorporate and release therapeutically relevant quantities of siRNA in a controlled fashion 
to yield rapid chronic wound closure.  This electrostatic assembly not only protects the siRNA 
from degradation, its release leads to in situ polyplex formation that promotes uptake of the 
material[21].  In the end, this work establishes a method for directly releasing siRNA into wound 
beds in a sustained manner that achieves sufficient knockdown to address the dysregulation 
associated with chronic wounds.  The modularity of the system and the ability to apply it directly 
to tissues further suggests that analogous LbL siRNA release                                                   
systems could be used in a similar fashion to address other types of wound dysregulation.  These 
findings also provide support for further investigations into the role of MMP-9 overexpression in 
the pathology of chronic diabetic ulcers. 
RESULTS 
Layer-by-Layer Film Characterization  
Coatings for siRNA delivery are comprised of two film architectures arranged in a hierarchical 
fashion.  The first film assembled directly on the woven nylon substrate is a two-component film 
of poly(β-amino ester) 2 (Poly2) and dextran sulfate (DS), referred to as [Poly 2/DS]x where x 
represents the number of architecture repeats.  Poly 2 is a well-established hydrolytically 
degradable polycation that facilitates water-based erosion in multilayer films[22].  On top of this 
degradable undercoating (designated as X) is an siRNA-containing LbL film (designated as Y) 
assembled from chitosan (Chi), reported in literature for its capability to complex with siRNA 
and facilitate cell uptake and delivery of nucleic acids, and siRNA that we refer to as 
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[Chi/siRNA]y (Fig. 1a-d).  This film architecture was chosen from an initial broad investigation 
of LbL film assemblies; exhibiting a range of release profiles ranging from hours to weeks and 
varying in vitro efficacies (Supplementary Table 1).  Iterations of this film structure, varying 
the number of layers of each component architecture independently, were investigated to 
determine the tunability of the overall architecture. LbL films often exhibit interpenetration of 
film layers[23]; furthermore, films containing weakly charged components or weak polyacids or 
amines can undergo interdiffusion and mixing during film assembly[24].  Increasing the number 
of layers of the underlying degradable sets of layers (X) can yield slower release overall due to 
the overall increased thickness of the film, which impacts water diffusion and surface based 
erosion of the film, and a longer timeframe for complete degradation of the underlying layers X, 
which may be partially intermixed with the drug loaded layers Y due to interdiffusion.  
Confocal imaging using a fluorescently labeled siRNA within the film shows high film 
uniformity with only minor defects (Fig. 1c and Supplementary Fig. 1).  Assembled films are 
sub-micron in thickness (up to approximately 320 nm) and incorporate siRNA at a rate of 0.56 ± 
0.11 µg/cm2 per layer deposited, reaching 13.9 ± 0.8 µg/cm2 after 25 bilayers (Fig. 1e-f).  In 
vitro, the film-coated bandages sustain the release of siRNA for up to two weeks and this release 
can be readily tuned by varying the film architecture (Fig. 1g-h).   
In Vitro Evaluation of Coated Bandages 
Several variations of this basic film architecture were investigated to determine the most 
effective film in vitro for more focused in vivo testing. NIH-3T3 cells expressing the reporter 
gene green fluorescent protein (GFP) were exposed in culture to film-coated bandages containing 
either a GFP-specific or control siRNA (siControl) sequence (Supplementary Table 2).  The 
knockdown of GFP was assessed after five days of treatment by measurement of the mean cell 
fluorescence (MCF) using flow cytometry.  The number of siRNA-containing layers 
significantly impacts the extent of GFP knockdown, with the greatest reduction in MCF being 
achieved by [Poly2/DS]20[CHI/siRNA]25 (Fig. 2a).  These experiments demonstrate the tuning 
capabilities of this platform, achieving low to moderate to high levels of gene silencing by 
making simple changes to the number of film architecture repeats.  In all cases, film-coated 
bandages exhibit minimal impact on cell viability relative to uncoated bandages, with all test 
groups maintaining better than 85 percent relative cell viability (Fig. 2b).  Degradation studies 
indicate that the rate of release of film material from coated bandages depends on the presence 
and number of layers of the degradable undercoating; films with 20 degradable layers result in 
significant knockdown and film degradation (Fig 2a,c), however films consisting of 10 or fewer 
degradable layers have incomplete release of siRNA and reduced knockdown after five days. 
We chose [Poly2/DS]20[CHI/siRNA]25 as the best architecture for further study due to the 
highest level of siRNA incorporation, release, and siRNA-specific gene knockdown.  A time 
course study of knockdown for this architecture in three distinct cell lines expressing GFP found 
a significant reduction in expression after three days (GFP reduction ranging from 25-35%) (Fig. 
2d).  Furthermore, knockdown of GFP in all cell lines persisted throughout the one-week period 
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of testing, with a reduction in GFP expression reaching 45-50% at day seven. The impact of the 
film coating on the viability of three different cell lines is minimal, with all cultures maintaining 
greater than 80 percent viability compared to cells treated with uncoated substrates (Fig. 2e).  
The cellular uptake of released film material over time was followed using a fluorescently 
labeled siRNA for one week in vitro (Fig. 2f).  The material was observed to accumulate in 
punctate localizations within the cell, and at extended times stain the entire cell body, indicating 
endosomal uptake and escape of siRNA to the cytosol (Supplementary Fig. 3). 
In Vivo Silencing of MMP-9 in a Diabetic Mouse Model 
With the success of the bandages in vitro, we next evaluated their efficacy in vivo using the 
db/db mouse, a genetically diabetic mouse model that has been well established for chronic 
ulcerative wound healing[25].  MMP-9 is overexpressed in this model in agreement with many 
human DFU patients, making it an ideal animal model for this in vivo investigation[26].  Three 
treatment groups were established; mice either received siMMP-9 (1), siControl (2), or uncoated 
(3) bandages (two wounds per mouse, n = 5 mice per group) (Supplementary Tables 3-4).  The 
film with maximal knockdown and performance, [Poly2/DS]20[Chi/siRNA]25, was chosen for the 
mouse model studies. The application of the dressings in vivo followed the steps outlined in Fig. 
3a.  Briefly, two 6mm diameter full-thickness wounds were excised from the dorsum of each 
mouse and a single bandage is placed over each wound site. The bandages were then secured in 
place using a commercially available adherent bandage.   Wounds were imaged after one and 
two weeks of treatment at necropsy (Fig. 3b).  After one week, thick tissue bridges the wounds 
treated with siMMP-9 bandages in contrast to poor tissue growth in the wounds of the control 
groups.  At two weeks the siMMP-9 treated wounds are significantly smaller and appear to have 
contracted, with substantial formation of tissue within the wound bed.      
Immunohistochemical (IHC) staining for MMP-9 shows a significant reduction within the 
wounds of mice treated with siMMP-9 films compared to controls.  Wounds from mice treated 
with either uncoated and siControl bandages show intense deep IHC staining at the wound edge, 
while wounds treated with siMMP-9 bandages have a diffuse low level of staining, indicating 
substantial changes in MMP-9 levels (Fig 3 c).  The expression of MMP-9 within wounds treated 
with siMMP-9 bandages is reduced by nearly 60 percent compared to controls after one week, 
which increases to over 75 percent after two weeks (Fig. 3d&g).  Similarly, the activity of 
MMP-9 within these wounds decreases by 46.2% ± 9.1% after one week and 55.0% ± 5.8% after 
two weeks (Fig. 3e&h).  Together these data demonstrate a significant change in MMP-9 
expression within the wound bed and point to a major change in the proteolytic 
microenvironment during the growth of new tissue. 
MMP-9 Knockdown Improves Wound Healing 
Histological analysis of wound healing was performed using serially sectioned wounds to create 
a two-dimensional estimate of the epithelial and panniculus carnosus (PC) muscle closure 
compared to the initial wound.  Figure 4a-b shows representative histological sections from 
wounds for each of the treatment groups after one and two weeks respectively (Supplementary 
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Fig. 4).  The difference between the degree of epithelial closure and the formation of granulation 
tissue of the different treatment groups is very pronounced.  Since the role of MMP-9 within the 
dermis is to degrade the ECM, we anticipated that its reduction in the wound would promote the 
accumulation of granulation tissue within the wound bed.  Quantification of the granulation 
tissue thickness in the center of the wound bed shows that wounds treated with MMP-9 siRNA 
bandages are nearly twice as thick as controls after one week, which increases to three-fold after 
two weeks (Fig. 4c).  This granulation tissue functions as a scaffold for epithelial migration 
across the wound as well as a substrate for contractile forces to close the wound, and we 
hypothesize that this is the reason wounds treated with siMMP-9 bandages exhibit significantly 
more advanced re-epithelialization and contraction as compared to controls (Fig. 4d).  The 
granulation tissue formed within wounds treated with siMMP-9 bandages is more cellular and 
more vascularized than that of the controls (Fig. 4 e-f).  After two weeks, siMMP-9 wounds 
contain nearly three times the number of vessels per viewing field as controls, with many vessels 
apparent in the center of the wound which are not seen in controls.  
siMMP-9 Therapy Increases Granulation Tissue Formation 
One of the major substrates for MMP-9 within the healing wound is the early collagen that forms 
granulation tissue.  By reducing the expression of MMP-9, we hypothesized that the granulation 
tissue would contain more collagen.  Masson’s trichrome (MTC) stain is a well-established 
histological stain for the analysis of collagen within tissues.  In tissues stained using this 
technique, collagen appears blue while cell bodies, muscle, and keratin are red.  This allows for 
the qualitative evaluation of collagen content and cellularity of tissue.  Analysis of MTC staining 
of wound sections reveals deep staining for collagen within the granulation tissue of siMMP-9 
treated wounds, while control groups have diffuse filamentous staining (Fig. 5a-b and 
Supplementary Fig. 5).  The cellularity of this granulation tissue is also increased. Furthermore, 
integration of the granulation tissue into the surrounding uninjured dermis is noticeably enhanced 
in the siMMP-9 treatment group versus control (Fig. 5c-d).  
Collagen Content is Increased in siMMP-9 Treated Wounds 
To further evaluate collagen accumulation within the wound we use a second independent 
histological technique: picrosirius (PS) staining of collagen.  Collagen within the dermis is a 
naturally birefringent macromolecule and large collagen fibers can be evaluated using polarized 
light microscopy.  PS staining of collagen greatly enhances this birefringence, allowing for the 
precise localization of small fibrils of collagen as well as thicker fibers and the distinction 
between the two[27].  Histological analysis of PS stained tissues has been used widely within the 
study of wound healing to evaluate the extent and type of collagen present within the healing 
tissue[28].  The PS stain is bright red in bright field microscopy.  When PS stained slides are 
imaged between crossed-polarizers, however, the thinner early Type III collagen appears blue-
green and the thicker and more mature Type I collagen appears orange-red. 
Here we use this method to evaluate the maturation of the granulation tissue within the wound 
bed and its collagen content (Fig. 6a-b).  After one week of treatment, granulation tissue in 
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MMP-9 siRNA treated mice has nearly twice the collagen content compared to control wounds, 
as well as twice as much mature collagen (Fig. 6 c-d).  At two weeks of treatment the wounds of 
MMP-9 siRNA treated mice contain nearly five times the collagen compared to either control 
group, and the ratio of mature to young collagen is increased over four-fold compared to the 
control groups.   
The significant difference between the siMMP-9 treated wounds and those of the control mice is 
striking.  Thick orange-red collagen bundles are seen to stretch though the formed tissue, 
whereas in the control groups only small blue-green fibers are appreciably present. These data 
suggest that not only does the knockdown of MMP-9 increase the amount of collagen within the 
wound bed, but also that its lowered expression allows for larger and more mature collagen 
fibers to develop within the tissue, more closely resembling uninjured dermis (Supplementary 
Fig. 6). 
When imaging the integration of the granulation tissue into the uninjured surrounding dermis, PS 
staining helps illuminate the collagen connecting the two tissues.  Integration into the 
surrounding tissue is key in promoting the infiltration of cells into the forming granulation tissue, 
and in diabetic ulcers this integration is significantly impaired[3, 6].  The wound edges of siMMP-
9 treated mice exhibit significantly higher collagen content, with large collagen bundles leading 
from the uninjured dermis into the granulation tissue.  SiControl and uncoated bandage treated 
mice have no such collagen, with little tissue leading out of the surrounding uninjured dermis 
(Fig. 6e).  Analysis of the orientation of the collagen also highlights the differences.  Collagen 
within the siMMP-9 treated wound edge is oriented, connecting between the dermis and the 
granulation tissue while no such alignment is seen in the control groups (Supplementary Fig. 7). 
DISCUSSION 
Diabetic foot ulcers are the number one cause of non-traumatic lower limb amputations in the 
United States and contribute an estimated $11 billion in annual cost to the US healthcare 
system[29].  The current therapeutic options for patients with DFUs have shown only limited 
success, with nearly half of treated patients unable to achieve full wound closure[8].  With the 
number of patients suffering from DFUs expected to nearly double in the next 20 years, there is a 
strong need to develop new therapeutic approaches to better address this disorder[30].   
Our motivation for targeting MMP-9 in this work is based on the substantial work of clinicians 
who have for over two decades correlated its overexpression to poor wound healing outcomes in 
diabetic patients[4, 6, 11].  However, until now there has been limited research focused on targeting 
this overexpression as a means of therapy[31], due in large part to the musculoskeletal side effects 
that has hindered the development of MMP inhibitors.  Through the use of layer-by-layer 
assembly we are able to construct a hydrolytically degradable siRNA depot on top of a 
commercially available nylon bandage that can deliver siRNA directly into a wound bed and 
dramatically alter gene expression.   
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The effect of siMMP-9 therapy closely resembles our initial hypothesis; by reducing the 
presence of MMP-9 to twenty percent of untreated tissue levels we diminish the overall protease 
activity by 60 percent. This allows more granulation tissue to form in the wound bed and the new 
tissue contains up to five-fold more collagen than untreated wounds. Overall, this additional 
collagen is more mature, and at the edges of the wound is more tightly integrated with the 
uninjured dermis.  We hypothesize that it is this substantial change to the deposited ECM that 
drives the observed improvement in healing by facilitating faster migration of the epithelial 
tongue and contraction of the wound.   
In summary, this study successfully demonstrates the use of electrostatic assembly to generate 
ultrathin siRNA coatings capable of direct and effective delivery of siRNA to a highly 
proteolytic wound environment.  This dramatically reduces the expression and activity of a key 
gelatinase and improves the healing of chronic wounds. Overall, this work begins to lay the 
groundwork for using localized RNAi to treat a clinically recognized dysregulation within 
diabetic ulcers and offers a potentially translatable strategy for improving patient care. The 
strategy outlined here, however, is not limited to treating chronic wounds. This technology is a 
simple and broadly applicable platform for including localized RNAi from any current medical 
device and has the potential to address a myriad of applications where altering localized protein 
express in specific tissue microenvironments may be of use, including cardiovascular diseases, 
transplant rejection, and cancer.  
MATERIALS AND METHODS 
Materials.  Poly 2 (20 kDa) was synthesized as previously reported.  Chitosan (15 kDa) and 
dextran sulfate (500 kDa) were purchased from Sigma Aldrich company (Manassas, VA).  
siRNA sequences were synthesized by Qiagen (Valencia, CA) (Supplementary Table 2).  
Woven nylon bandages, TegadermTM (3M), were purchased through Cardinal Health (Newark, 
NJ).  Phosphate-buffered saline (PBS, 10x), Advanced-MEM, fetal bovine serum, antibiotic-
antimycotic solution, and 100 mM L-Glutamine solution were purchased from Invitrogen 
(Carlsbad, CA).  GFP expressing NIH-3T3, HeLa, and MDA-MB-231 cells were purchased from 
Cell Biolabs (San Diego, CA). 
Layer-by-layer film preparation.  Films were deposited on oxygen plasma treated bandages.  
Bandages were cleaned in ethanol and then in RNase free UltraPureTM water (Life Technologies) 
prior to plasma treatment.  Oxygen plasma treatment was performed for 3 minutes on high 
setting.  Bandages were then immediately immersed in a solution of the polycation Poly 2 for a 
minimum of one hour.  Assembly of LbL films was performed using a Carl Zeiss HMS-DS50 
stainer.  [Poly 2/DS] base layers were deposited through sequential polymer adsorption steps (2 
mg ml-1, pH 5.0) of 10 minutes.  Between each polymer deposition step the bandages were 
washed twice in RNase free water (pH 5.0).  Assembly of [CHI/siRNA] film was deposited 
similarly.  Chitosan (1mg ml-1, pH 5.0) was adsorbed for 10 minutes and siRNA (20 µg ml-1, pH 
5.0) was adsorbed for 15 minutes.  All solutions were prepared in RNase free water, adjusted to a 
pH of 5.0.   
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Film growth was characterized for films built on silicon wafers by a Veeco Dektak 150 
profilometer.  Incorporation of fluorescently labeled siRNA into films built on nylon bandages 
was followed using a Nikon A1R Ultra-Fast Spectral Scanning confocal microscope.  Total 
siRNA incorporation within films was measured by rapid dissolution in a 1M NaCl solution with 
vigorous agitation and quantified using a fluorescent plate reader.  Release studies were 
performed in PBS (pH 7.4, 37°C).  Release was quantified by fluorescence of the released 
labeled siRNA read using a fluorescent plate reader.   
In Vitro LbL Bandage Evaluation.  Cells were cultured in Advanced-MEM media with 5% 
FBS, 1% antibiotic-antimycotic, and 2mM L-glutamine.  Cells were seeded at an initial density 
of 5,000 cells per well in a 48-well plate.  After one day LbL coated bandages (0.25cm2 sections) 
were placed in culture with the cells.  The bandages either contained GFP-specific siRNA or a 
control siRNA sequence or were uncoated.  Uncoated bandages were used as the control to test 
the cytotoxicity of the film.  Mean cell fluorescence was measured by flow cytometry, using a 
BD FACSCalibur flow cytometer.  Cell viability was quantified using AlamarBlue assay (Life 
Technologies). 
In Vivo siRNA Delivery.  All animal studies were approved by the MIT Institutional Animal 
Care and Use Committee (IACUC).  Animals were housed and cared for in the USDA-inspected 
MIT Animal Facility under federal, state, local, and NIH guidelines for animal care.  Eight week 
diabetic (db/db) mice (BKS.Cg-Dock7m +/+ Leprdb/J) were purchased from Jackson Labs (Bar 
Harbor, ME).  Daily blood glucose measurements were taken for all mice used.  Mice were 
required to maintain a blood glucose level in excess of 300mg dl-1 to be used for these studies.  
Three groups of mice were used: (1) MMP-9 siRNA bandage treated, (2) control siRNA bandage 
treated, and (3) uncoated bandage treated.  Each group had 10 mice total, 5 mice per time point.  
Hair was removed from the backs of mice using a depilatory cream under anesthesia at least one 
day prior to surgery.  Surgeries were performed under anesthesia and pre-operative analgesic was 
given to all mice (0.1 mg kg-1 Buprenex).  Two 6mm full-thickness wounds were excised from 
the dorsum of mice using a biopsy punch on either side of midline.  Bandages were cut to the 
same size (6mm dia.) as the wound and placed on top of the wound.  The bandages were then 
secured in place using an adherent Tegaderm.  This securing bandage holds the test bandage in 
place as well as keeps cage material from entering the wound. Mice were sacrificed after one and 
two weeks of treatment.  One wound from each mouse was used for histological analysis and one 
wound was used for RNA isolation and protein analysis. 
Histology.  Tissues were fixed in zinc fixative without formalin for 48 hours.  The excised 
wounds were then embedded in paraffin and serially sectioned at 250µm levels throughout the 
wound.  At each level an H&E slide was stained and used for 2-D reconstruction of the wound.  
Unstained slides were also taken for IHC, MT, and PS staining and analysis of the healing tissue.  
Data analysis was performed using Image J.  Orientation of collagen fibers was analyzed using 
the Image J plugin Orientation J. 
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Tissue Processing.  Isolation of RNA was performed using TRIzol as per the manufacturer’s 
instructions.  Synthesis of cDNA was done using iScript cDNA synthesis kit (Bio-Rad 
Laboratories) and analysis of expression was performed by qRT-PCR using iQ SYBR Green 
Supermix (Bio-Rad Laboratories) along with selected DNA primer pairs.  All experiments were 
performed in triplicate using a LightCycler 480 (Roche).  Relative gene expression was 
quantified relative to β-actin, a housekeeping gene, using the delta-delta Ct method 
(Supplementary Table 3).  Analysis of MMP-9 activity within wound tissues was performed as 
previously described12.  Briefly, total protein concentration of tissue homogenates was measured 
using BCA Protein Assay (Pierce Biotechnology) as per the manufacturer’s instructions.  The 
concentration of total protein was normalized between groups.  MMP-9 activity was then 
measured using Sensolyte® Plus 520 MMP-9 Assay Kit (AnaSpec) as per the manufacturer’s 
instructions.  All experiments were performed in triplicate.   
Statistics.  Statistical analysis was performed between groups using Student’s t-test and rectified 
by ANOVA for comparisons between multiple groups.  Values are represented as mean ± s.d.  A 
value of p < 0.05 was used to indicate statistical significance. 
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FIGURE CAPTIONS 
 
Figure 1 LbL coating for sustained release of siRNA.  (a) Chemical structures of polymers used in this work.  (b)  
Schematic of the hierarchical structure of LbL films into a single coating.  The first (X) film is a hydrolytically 
degradable undercoating, while the second (Y) film contains the siRNA to be delivered.  (c) Fluorescently labeled 
siRNA is shown to coat the entire woven structure of the nylon bandage.  Image used to create the projection (1-4) 
show the conformal nature of the coating.  (d) Side-on schematic of hierarchical LbL film architecture.   (e) 
Incorporation of siRNA was observed to increase in a near-linear fashion over the tested range.  (f) Film thickness 
was observed to increase with the number of layers assembled.  Films were assembled on either X = 0, 10, or 20 
degradable baselayers.  All films tested were sub-micron thick with the thickest reaching nearly 325nm after 25 
siRNA containing layers on top of 20 degradable baselayers.  (g) Release of siRNA from coated bandages with 
varying numbers of degradable baselayers.  Release was performed out to 14 days in PBS at 37°C.  (h) Release of 
siRNA from coated bandages with varying numbers of siRNA containing layers assembled on 20 degradable 
baselayers.  All films achieved near complete siRNA release within the 14 day test period.  Release performed in 
PBS at 37°C.  
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Figure 2  In vitro analysis of reporter gene knockdown and film behavior.  (a) Analysis of mean cell fluorescence 
(MCF) as measured by flow cytometry after five days of treatment.  Values are shown relative to MCF values for 
cells treated with bandages containing control siRNA (n = 3).  (b)  Impact of films on cell viability quantified by 
AlamarBlue assay, shown relative to measurements of cells treated with uncoated bandages(n = 3).  (c)  Scanning 
electron micrographs of LbL film coated bandages, (1) no coating, (2) [Chi/siRNA]25, (3) 
[Poly2/DS]10[Chi/siRNA]25, (3) [Poly2/DS]20[Chi/siRNA]25 after five days degradation in culture with cells. Scale 
bar = 20µm.  (d)  Relative MCF of GFP expressing NIH-3T3, MDA-MB-231, and HeLa cell lines after 3 (black 
bar), 5 (gray bar), and 7 (white bar) days of treatment (n = 3).  MCF is reduced in all cell lines tested, with the 
reduction maintained over the one-week test period.  (e)  Impact on cell viability is minimal for all cell lines tested 
over one week. (f) Uptake of fluorescently labeled siRNA by NIH-3T3 cells in culture with coated bandages after 3, 
5, and 7 days respectively.  Scale bar = 15µm.  Data is shown as mean ± s.d., * p<0.05. 
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Figure 3 In vivo application of MMP-9 siRNA coated bandages improves the gross appearance of wounds and 
reduces MMP-9 expression and activity within the treated wounds.  (a)  Schematic of how bandages are applied to 
the full-thickness excisional wounds on the backs of mice.  (1) A six mm diameter wound is excised from the back 
of the mouse (one on each side).  (2) The test bandage is placed over the wound site.  (3)  The bandage is held in 
place by an adherent semi-clear bandage.  (b) Digital imaging of wounds immediately following surgery (Day 0), 
and after 7 or 14 days of treatment.  Scale bars, 5 mm. (c) IHC staining of MMP-9 within the wound edges of 
uncoated (1&4), siControl (2&5), and siMMP-9 (3&6) bandage treated wounds.  Arrows highlight regions of 
intense staining.  Scale bars, 50 µm. (d&f) Quantitative real time PCR analysis of MMP-9 expression relative to the 
housekeeping gene β-actin after one week (d) and two weeks (f) of treatment. (e&g)  Activity of MMP-9 within 
wound homogenates as measured by Senso-lyte 520 MMP-9 activity kit after one week (e) and two weeks (g).  Data 
is shown as mean ± s.d., * = p<0.05. 
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Figure 4  Hematoxylin and eosin histological analysis of wound healing.  (a-b) H&E stained wound sections after 
one week (a) and two weeks (b) of treatment with siMMP-9 (1), siControl (2), and Uncoated (3) bandages.  Black 
arrows highlight the epithelial tongue and white arrows point to the end of the PC muscle.   Scale bars, 1 mm. (c)  
Percent closure of the epithelial and PC muscle gaps evaluated at one and two weeks of treatment.  (d)  Granulation 
tissue thickness in the center of wounds after one and two weeks.  (e)  High power field (HPF) (40x) imaging of the 
center of wound granulation tissues in siMMP-9 (1), siControl (2), and Uncoated (3) treated wounds.  Arrows 
highlight some of the vessels visible in H&E staining.  Scale bar = 100µm (f)  Number of vessels per HPF, n = 9 per 
group. Data is shown as mean ± s.d., * = p<0.05. 
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Figure 5 Treatment with MMP-9 siRNA increases the collagen content of the formed granulation tissue.  (a)  
Masson’s trichrome (MTC) stained wound sections of the center of wounds after two week of treatment of (1) 
MMP-9 siRNA, (2) Uncoated bandage, (3) Control siRNA treated wounds. Scale bar, 1 mm. (b) MTC stained 
granulation tissue within the center of the formed tissue shows significantly more collagen (blue stain) within the 
MMP-9 siRNA treated wounds (1) when compared to either uncoated (2) or control siRNA bandage (3) treated 
wounds.  Scale bar, 100 µm. (c & d)  Comparison of the wound edges showed significantly more tissue growth out 
of the wound edge in MMP-9 siRNA treated wounds (d) than control siRNA (c) treated wounds.  Scale bar, 100 µm. 
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Figure 6 Treatment with MMP-9 siRNA increases collagen content and retention within the 
formed granulation tissue.  (a) Picrosiruis stained wound sections after one and two weeks of 
treatment with siMMP-9 (1) siControl (2) Uncoated (3) bandages.  Scale bars, 75 µm. (b) 
Imaging of birefringent collagen through crossed-polarizers.  Collagen type can be ascertained 
by the thickness of fibers, with collagen Type I being large orange-red fibers and Type III being 
thin green filamentous fibers.  Scale bars, 75 µm.  (c) Fraction of the granulation tissue within 
the wound that stains red for collagen.  (d) The major type of collagen within the formed 
granulation tissue was significantly different between groups.  Groups treated with siMMP-9 saw 
nearly twice as much Type I collagen after one week compared to controls, which increased to a 
near five-fold difference after two weeks. (e) Tissue infiltration and wound edge integration is 
enhanced in wounds treated with siMMP-9 bandages.  (1-3) Picrosirius red staining of wound 
edge.  (UD = Uninjured Dermis, GT = Granulation Tissue).  (4-6) Birefringent collagen imaging 
using crossed polarization light microscopy.  (7-9) Color map of fiber orientations.  This is 
performed using OrientationJ software[32].  Fiber orientation is only seen in the siMMP-9 
treatment group.  Scale bars, 75 µm. Data is shown as mean ± s.d., * = p<0.05, ** = p < 0.01. 
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